BR1019 not checked

Boryung Pharmaceutical Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Subjects take the investigational products once a day for 12 weeks.”In the company’s words, NCT06220773 on ClinicalTrials.gov
Tested for
Essential Hypertension, Type 2 Diabetes Mellitus
Main trialPhase 3
“The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus”In the company’s words, NCT06220773 on ClinicalTrials.gov

Other drugs for Essential Hypertension

All 18 drugs for Essential Hypertension

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Dec 2026 A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Phase 1Completed 31 Mar 2024 A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
Phase 1Completed 11 Dec 2024 A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BR1019

Following is part of Solo: you see every change to BR1019 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in